Phase 1/2 Lyme Vaccine Study
This study is currently recruiting participants.
Verified January 2012 by Baxter Healthcare Corporation
First Received on December 22, 2011. Last Updated on January 3, 2012 History of Changes
Sponsor: Baxter Healthcare Corporation
Information provided by (Responsible Party): Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT01504347
The purpose of the study is to obtain safety and immunogenicity data of different dose levels of a multivalent recombinant OspA Lyme Borreliosis (mv rOspA LB) Vaccine with and without adjuvant in seronegative healthy adults aged 18 to 70 years. The outcome shall provide the basis for dose/formulation selection for Section 2 of the study.
An additional purpose of the study is to evaluate the safety and immunogenicity of the optimal dose(s)/formulation of the mv rOspA LB Vaccine in a larger population of seronegative and seropositive healthy subjects aged 18 to 70 years.